Background: Transplant coronary artery vasculopathy (TCAV) is the major cause of late allograft failure and death in heart transplant recipients. The aim of this systematic review was to examine the outcomes of percutaneous coronary interventions (PCIs) as compared to coronary artery bypass grafting (CABG) surgery in the management of TCAV. Our secondary objective was to compare the use and outcomes of drug eluting stents (DES) as compared to bare metal stents (BMS) in this patient population.
Introduction
Cardiac transplantation is the definitive therapy for patients with end stage heart failure refractory to medical management (1, 2) . Transplant coronary artery vasculopathy (TCAV) remains the most common cause of late allograft failure and death after 1 year (3). The prevalence of TCAV has been reported to be 8%, 30% and 50% at 1, 5 and 10 years post heart transplantation, respectively (3) .
In contrast to coronary artery disease (CAD) that is associated with focal atherosclerotic calcium plaque formation, TCAV is a panarterial disease in which there is diffuse vessel narrowing due to concentric fibroproliferative lesion of the intima without calcium deposition (4) . In addition to morphological differences, a different set of risk factors has also been suggested in the development of TCAV as compared to CAD. The pathophysiology of TCAV is multifactorial and involves both immunological and nonimmunological mechanism. Immunological factors that have been suggested include HLA mismatching, T cell activation, cytomegalovirus infection, older donor, younger recipient and presence of recipient pretransplant cardiovascular risk factors (5) (6) (7) . Nonimmunological factors include endothelial injury, ischemia-reperfusion injury and risk factors for CAD, predominantly hyperlipidemia and diabetes (8, 9) .
Therapeutic strategies that exist in the prevention of TCAV are limited. Options for management of TCAV include immunosuppressive therapy, coronary allograft revascularization [percutaneous coronary intervention (PCIs), coronary artery bypass grafting (CABG)], or heart re-transplantation (10) (11) (12) . Heart re-transplantation is the definitive management of TCAV in this group of patients, but is limited by the scarcity of suitable donor organs (13) . Despite extensive literature regarding the use of PCI and CABG in the management of CAD, there is a paucity of data about the efficacy of such interventions in TCAV.
The primary objective of this systematic review was to examine the outcomes of PCI as compared to CABG in the management of TCAV. Our secondary objective was to compare the use and outcomes of drug eluting stents (DES) as compared to bare metal stents (BMS) among patients who underwent PCI for TCAV.
Methods

Literature search strategy
Thorough electronic searches were performed in August 2017 using Ovid Medline, Embase, Cochrane Central Register of Controlled Trials (CCTR), Cochrane Database of Systematic Reviews (CDSR), Web of Science, Scopus and CINAHL. To achieve the maximum sensitivity of the search strategy, we combined the terms: "heart transplant", "cardiac transplant", "coronary artery disease", "myocardial infarction", "myocardial ischemia", "vasculopathy", "coronary stenosis", "revascularization", "angioplasty", "stent" and "coronary artery bypass" as either key words or MeSH terms. The reference lists of all retrieved articles were reviewed for further identification of potentially relevant studies, assessed using the inclusion and exclusion criteria.
Selection criteria
Eligible studies for the present systematic review and metaanalysis included those that addressed TCAV amongst heart transplant recipients. When institutions published duplicate studies with accumulating numbers of patients or increased lengths of follow-up, only the most complete reports were included for quantitative assessment with no overlapping time intervals. We excluded studies on patients <18 years of age, studies not published in the English language and those not involving human subjects. Furthermore, abstracts, case reports, conference presentations, editorials, reviews and expert opinions were also excluded.
Data extraction and critical appraisal
Data was extracted from article texts, tables and figures (JH Choi, JG Luc). Discrepancies between the two reviewers were resolved by discussion and consensus.
Statistical analysis
A meta-analysis of proportions was conducted for the available main perioperative and postoperative variables with logit transformation. Heterogeneity was evaluated using Cochran Q and I 2 test. Meta-regression was conducted 
Results
Study characteristics
Overall, 4,989 records were identified in the literature search that were published between 1968 and 2015. Following application of the inclusion and exclusion criteria, 29 studies were included for analysis, with a total of 1,520 patients and mean follow-up period of 30.8 months. A PRISMA flow diagram depicting the overall search strategy is provided in Figure 1 . These studies included 28 singlecenter studies, and 1 multicenter registry. Of the studies, 28 studies had retrospective patient enrolment and 1 study had prospective patient enrolment. Manual search of references did not yield further studies.
Baseline demographics
Baseline demographics are shown in Table 1 . Mean patient age was 54.4 years (95% CI, 52.66-56.06) with 78.6% being male. Patient comorbidities include hypertension (80.0%), diabetes (35.8%), dyslipidemia (69.5%), prior myocardial infarction (20.5%) and obesity (53.3%). Etiology of heart failure requiring heart transplantation was primarily ischemic cardiomyopathy (55.5%).
In terms of initial clinical presentation of TCAV, the majority of patients (55.4%) were asymptomatic with other variants of presentation including angina (24.8%), acute coronary syndrome (22.4%), congestive heart failure (18.3%) and myocardial infarction (10.6%) ( Table 2 ). The majority of involved lesions were those of the left anterior descending coronary artery (67.8%), followed by right (38.1%), left circumflex (32.6%) and left main coronary artery (7.1%) ( Table 3) .
Drug eluting versus BMS
Among the 303 patients who underwent PCI in studies reporting on stent type, 181 patients received DES (60%) and 122 patients received BMS (40%). Preoperative medications received among the cohorts are described in Table 5) . Furthermore, there were no significant differences between the DES and BMS cohorts in terms of survival (Figure 2A) , event-free survival ( Figure 2B ) and freedom from restenosis ( Figure 2C ) at 1, 2 and 3 years post PCI.
Discussion
Coronary allograft vasculopathy following heart transplantation has an incidence of 30-50% at 5 years (14) and remains the most common cause of late allograft failure and the major determinant for long-term survival (3). The mainstays of treatment include CABG, PCI or heart retransplantation (15) . Although the definitive management of TCAV is retransplantation, it is limited by the scarcity of suitable donor organs. Therefore, retransplantation is usually reserved for patients with disease progression despite revascularization or those with diffuse coronary Ann Cardiothorac Surg 2018;7(1):19-30 www.annalscts.com Table 4 Medications administered in DES involvement (13) . Limited studies have compared the outcomes of CABG and PCI in the management of TCAV. In this systematic review and meta-analysis, we demonstrate that both CABG and PCI are feasible modalities for revascularization in patients with TCAV, where PCI is associated with lower mortality and no difference in cardiac mortality during the same follow up period. Furthermore, among those who underwent PCI, there were no differences in outcomes in terms of mortality, event-free survival or freedom from restenosis for patients who received a DES compared to a BMS.
In contrast to CAD in the general population, TCAV has significant morphological differences and risk factors (4), and has been thought to be a manifestation of chronic rejection (16) . Preventative strategies for TCAV include treatment of immunological (anti-HLA, chronic inflammation and acute rejection via optimization of immunosuppressive therapy) and nonimmunological factors (e.g., hypertension, hyperlipidemia and pre-existing diabetes) (17) . Early post-transplant coronary angiography is often obtained in recipients of higher risk donor hearts to screen for the presence of pre-transplant coronary artery disease as there has been shown a correlation between the presence of pre-transplant coronary artery disease and the incidence and severity of TCAV (18) .
We demonstrate that CABG in patients with TCAV was associated with higher mortality (P<0.001), though no significant difference was found in cardiac-related mortality (P=0.362). Furthermore compared to PCI, CABG in patients with TCAV was accompanied with a decreased need for repeat intervention 15.4% vs. 37.2% that did not reach statistical significance (P=0.327) during the same follow-up period. Given the aforementioned outcomes, it is vital to interpret the results with care, whilst keeping in mind the threshold for revascularization in this often asymptomatic group of patients. There is significant heterogeneity in CABG early mortality outcomes for patients with TCAV (10, 14, 18, 19) , which is likely due to the limited number of patients in each study, differences in patient selection, treatment bias, and changes in medical management and surgical practice across the decades. Furthermore, in the present study, average time from heart transplantation to revascularization was shorter (P<0.001) with more patients with TCAV involving the left main coronary artery in the CABG subgroup as compared to the PCI group (P<0.001). As such, despite a higher incidence of TCAV with left main involvement in the CABG cohort, CABG cannot be advocated readily and indiscriminately given the significant early morbidity and mortality.
Prior decision algorithms have suggested that CABG can be performed in the subgroup of heart transplant patients with Type A lesions, whereby Type B/C lesions are not amenable to bypass surgery (20) . However, the decision for CABG surgery should depend on other factors as well, factors including adequate artery size (minimum of 1.8 to 2 mm), whether the combination of lesions at different stages are bypassable, and whether the lesions are hemodynamically significant (14) . Other factors that warrant consideration in patient selection include the patient's overall physiological and functional status, comorbidities, likelihood of achieving complete revascularization, and whether alternative surgical approaches such as off-pump techniques are applicable (14) .
PCI in patients with TCAV has been associated with greater restenosis rates compared to PCI in patients with native CAD (21) . As DES has been shown to reduce restenosis when implanted in native coronary arteries (22) (23) (24) , we compared the use and outcomes of DES vs. BMS among patients who underwent PCI for TCAV. In the present study, there was a non-significant higher freedom from restenosis at 1, 2 and 3 years among those who received a DES as compared to a BMS with no significant difference in mortality. Existing reports share a common experience (25, 26) . Similarly, a meta-analysis of six different studies found no difference in terms of major adverse cardiac events (MACE) or all-cause mortality between DES vs. BMS (27) . Reasons postulated as to why DES did not affect MACE or all-cause mortality is that TCAV is a diffuse and progressive process, that a focal lesion is a marker of widespread disease (28) , and that repeat intervention will remain common regardless of method of PCI.
Due to the denervation of the afferent cardiac nervous system and absence or incomplete reinnervation of the cardiac allograft, most heart transplant patients present asymptomatically, and if at all, with atypical angina (20) , as is evidenced in our current study. Therefore, the first clinical manifestations of coronary allograft ischemia predominantly include congestive heart failure, ventricular arrhythmias, silent myocardial infarction, or sudden cardiac death (29) . As such, given its asymptomatic nature and progressive nature of TCAV, close and frequent surveillance for heart transplant recipients is necessary. Noninvasive studies such as the treadmill test or myocardial perfusion studies have been demonstrated to have limited clinical utility due to poor sensitivity for TCAV, owing to the diffuse nature of the disease which does not allow for assessment of differential myocardial blood flow on radionuclide scans (16) . Dobutamine echocardiographic stress test has been shown to be a more sensitive noninvasive screening test than the former noninvasive tests, nonetheless angiography remains the current gold-stand in diagnosis and characterization of lesions (16) . The incremental levels of sensitivity from noninvasive to invasive tests for TCAV are demonstrated in the current study, where the majority of TCAV were found on angiography. However, angiography has been shown to underestimate the presence and severity of TCAV (20) . Intravascular ultrasound imaging (IVUS) has been proposed as a more sensitive means of detecting intimal vascular wall thickening and may be an important tool for ensuring optimal stent deployment, reducing stent under-expansion, incomplete stent apposition, edge dissection or geographic miss (30) .
Limitations
This meta-analysis has several key limitations and must be interpreted with care. Regional differences exist in patient and donor selection, center experience, heart transplantation techniques, immunosuppressive regimes used and clinical management of heart failure. We acknowledge that this heterogeneity in study population is a fundamental limitation that cannot be addressed due to inability to extract sufficient detail from the pooled data. Due to the lack of detail in the data, we were unable to stratify CABG outcomes by era or analyze and compare multi-lesion interventions separately. Pooled results may not correctly reflect the advancements made during the last five decades of this widely performed procedure. n/N variation amongst variables reported led to fluctuation in pooled number results. Moreover, the heterogeneity in results precludes broad generalization into prognostic terms. The impact of CABG and PCI in patients with TCAV on survival and freedom from restenosis is difficult to assess due to the limited number of patients, lack of detail precluding the ability to differentiate patients who underwent complete vs. partial revascularization, and incomplete clinical and angiographic follow-up for some of the patients. Furthermore, inconsistent definitions were used to describe the outcomes and CABG and PCI in terms of restenosis and clinically significant coronary lesions, with inconsistent criteria for the need for repeat reintervention. It is possible that patients undergoing PCI represented a population that was less sick than the population that underwent CABG, thereby overestimating the benefit of PCI. As well, patients who underwent CABG as compared to PCI may be different and represent different states in the natural course of progression of TCAV. It is also plausible that outcomes of revascularization may have been influenced by clinical presentation rather than treatment modality.
In view of improving success of cardiac transplantation, a larger number of patients with TCAV can be anticipated to present in need of therapy. It is hoped that advances in noninvasive methods to improve screening for TCAV using either imaging studies (31) or noninvasive markers (32) continue to expand for earlier diagnosis. Furthermore, ongoing research in TCAV and vascular biology to develop targeted preventive therapies, interventional and surgical therapeutic approaches are needed to tailor management and improve outcomes. Decisions regarding CABG vs. PCI are likely to continue to remain difficult and it is our hope that the present study forms the basis for future studies as well as provides a platform for dialogue and collaboration amongst multiple disciplines to work towards reducing the number of grafts lost to TCAV. Randomized controlled trials or prospective registry analysis with clinical and angiographic data comparing outcomes of CABG vs. PCI for patients with TCAV would be invaluable.
Conclusions
The results of our systematic review of 29 studies consisting of 1,520 patients with TCAV demonstrate that CABG and PCI are both feasible modalities for revascularization in patients with TCAV, with PCI being associated with lower mortality. There were no differences in outcomes among patients who underwent PCI with DES as compared to BMS. Further studies are needed to delineate evidencebased guidelines to tailor the appropriate therapy, CABG or PCI, to the appropriate patient with TCAV.
